Penfluridol (formerly TLP-607; McN-JR-16341; R-16341; Acemap; Semap) is a 1st generation, long-acting and diphenylbutylpiperidine-based antipsychotic medication used for maintenance/long-term treatment of schizophrenia or other psychotic disorders.

Physicochemical Properties

Molecular Formula	C28H27CLF5NO
Molecular Weight	523.97
Exact Mass	523.17
Elemental Analysis	C, 64.18; H, 5.19; Cl, 6.77; F, 18.13; N, 2.67; O, 3.05
CAS #	26864-56-2
Related CAS #	26864-56-2
PubChem CID	33630
Appearance	White to off-white solid powder
Density	1.3±0.1 g/cm3
Boiling Point	587.7±50.0 °C at 760 mmHg
Melting Point	105-107ºC
Flash Point	309.2±30.1 °C
Vapour Pressure	0.0±1.7 mmHg at 25°C
Index of Refraction	1.553
LogP	6.01
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	7
Rotatable Bond Count	7
Heavy Atom Count	36
Complexity	647
Defined Atom Stereocenter Count	0
SMILES	ClC1C([H])=C([H])C(=C([H])C=1C(F)(F)F)C1(C([H])([H])C([H])([H])N(C([H])([H])C([H])([H])C([H])([H])C([H])(C2C([H])=C([H])C(=C([H])C=2[H])F)C2C([H])=C([H])C(=C([H])C=2[H])F)C([H])([H])C1([H])[H])O[H]
InChi Key	MDLAAYDRRZXJIF-UHFFFAOYSA-N
InChi Code	InChI=1S/C28H27ClF5NO/c29-26-12-7-21(18-25(26)28(32,33)34)27(36)13-16-35(17-14-27)15-1-2-24(19-3-8-22(30)9-4-19)20-5-10-23(31)11-6-20/h3-12,18,24,36H,1-2,13-17H2
Chemical Name	1-[4,4-bis(4-fluorophenyl)butyl]-4-[4-chloro-3-(trifluoromethyl)phenyl]piperidin-4-ol
Synonyms	TLP-607; McN-JR-16341; R-16341; McNJR16341; R16341; TLP607; TLP 607; McN JR 16341; R 16341; Acemap; Semap
HS Tariff Code	2934.99.9001
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

Targets	Dopamine receptor ( Ki = 1.6 μM )
ln Vitro	In vitro activity: Penfluridol is a long-acting neuroleptic medication that can treat both positive and negative symptoms of schizophrenia. With a Ki of 1.6 μM, penfluridol prevents dopamine from binding to the dopamine receptor. It works as an antipsychotic by inhibiting dopamine projections in the mesocortical area and limbic system.[1] Penfluridol competitively opposes potassium-induced calcium-dependent contractions in the rat vas deferens and specifically blocks [3H]nitrendipine's binding to the cerebral cortical membrane fraction of the rat. Penfluridol (10 μM) inhibits calcium influx during either NE or KCl stimulation, as well as the contractile response of isolated rings of rabbit thoracic aorta to these stimuli.[2]
ln Vivo
Cell Assay	Cell Line: Human AML cell lines, HL-60 (FLT3-WT), U937 (FLT3-WT), and MV4–11 (FLT3-ITD) Concentration: 1.25, 2.5, 5, 10, 20, 40 μM Incubation Time: 24, 48 h Result: Significantly reduced cell viability in a concentration-dependent manner.
Animal Protocol	DBA/1J male mice aged 10–12 weeks with type II chicken collagen-induced arthritis (CIA) model 10 mg/kg Daily oral gavage; from the 18th day after the first immunization
References	[1]. Science . 1976 Apr 30;192(4238):481-3. [2]. Proc Natl Acad Sci U S A . 1985 Feb;82(4):1237-41.
Additional Infomation	1-[4,4-bis(4-fluorophenyl)butyl]-4-[4-chloro-3-(trifluoromethyl)phenyl]-4-piperidinol is a diarylmethane. One of the long-acting ANTIPSYCHOTIC AGENTS used for maintenance or long-term therapy of SCHIZOPHRENIA and other PSYCHOTIC DISORDERS.

Solubility Data

Solubility (In Vitro)

DMSO: ~100 mg/mL (~190.9 mM) Water: <1 mg/mL Ethanol: ~100 mg/mL (~190.9 mM)

Solubility (In Vivo)

Solubility in Formulation 1: ≥ 2.5 mg/mL (4.77 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (4.77 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (4.77 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.. Solubility in Formulation 4: 5%DMSO + 5%Tween 80 + 50%ddH2O: 5.0mg/ml (9.54mM)  (Please use freshly prepared in vivo formulations for optimal results.)

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	1.9085 mL	9.5425 mL	19.0851 mL
	5 mM	0.3817 mL	1.9085 mL	3.8170 mL
	10 mM	0.1909 mL	0.9543 mL	1.9085 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.